Filing Flows › Arbutus Biopharma (ABUS) › Q1 2026 › vs Q1 2025
Arbutus Biopharma (ABUS) Q1 2026 vs Q1 2025 (year over year)
Arbutus Biopharma's revenue rose $177M (102×) from $1.8M in Q1 2025 to $179M in Q1 2026. The biggest changes: Revenue from collaborations and licenses +$179M (—); Collaborations and licenses −$1.1M (-84%); Non-cash royalty revenue −$267K (-60%).
Arbutus Biopharma, Q1 2026: revenue $179M (102× year over year), operating margin 94.3%, net earnings $170M, operating cash flow −$8.1M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue from collaborations and licenses | $179M | $0 | $179M | — |
| Collaborations and licenses | $204K | $1.3M | −$1.1M | -84% |
| Non-cash royalty revenue | $181K | $448K | −$267K | -60% |
| Revenue | $179M | $1.8M | $177M | 102× |
| Other income, net | $787K | $1.2M | −$386K | -33% |
| Operating profit | $169M | −$25.7M | $195M | — |
| Costs & expenses | $10.2M | $27.5M | −$17.2M | -63% |
| Pre-tax earnings | $170M | −$24.5M | $194M | — |
| Research & development | $4.1M | $9.0M | −$4.8M | -54% |
| General & admin | $5.9M | $5.8M | $57K | +1% |
| Other operating costs | $209K | $12.7M | −$12.5M | -98% |
| Net earnings | $170M | −$24.5M | $194M | — |
| Operating cash sources | $179M | −$7.2M | $186M | — |
| Depreciation & amortization | $11K | $330K | −$319K | -97% |
| Share-based compensation | $1.4M | $3.6M | −$2.2M | -62% |
| Cash used in operations | $8.1M | $13.4M | −$5.3M | -39% |
| Working capital & other | $179M | −$7.2M | $186M | — |
Questions
How much did Arbutus Biopharma's revenue grow year over year in Q1 2026?
Arbutus Biopharma's revenue rose $177M (102×) from $1.8M in Q1 2025 to $179M in Q1 2026.
What drove Arbutus Biopharma's revenue change in Q1 2026?
Revenue from collaborations and licenses +$179M (—); Collaborations and licenses −$1.1M (-84%); Non-cash royalty revenue −$267K (-60%).